Sustained Treatment Success With Ustekinumab in Symptomatic Stricturing Crohn's Disease: A Retrospective Single‐Arm Observational Cohort Study
Jingwen Liu, Wen Hu, Shuyan Li, Shurong Hu, Deming Jiang, Yan Chen · 2026
Read Sustained Treatment Success With Ustekinumab in Symptomatic Stricturing Crohn's Disease: A Retrospective Single‐Arm Observational Cohort Study by Jingwen Liu, Wen Hu, Shuyan Li, Shurong Hu, Deming Jiang, Yan Chen (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/PMC13273843.txt.
Description
Liu and colleagues report a 2026 cohort study of ustekinumab for Crohn's disease with strictures in China. Strictures are narrowings of the bowel that block flow. The study followed adults who started the drug for symptomatic strictures.
Of 73 patients screened, 54 entered the study. At week 52, 44 patients, or 81.5 percent, met the success target. Success meant staying on the drug without banned add-on treatments. Most patients improved in blockage symptoms and disease activity scores. Scans, scope findings, and blood markers also improved. Non-smoking and C-reactive protein levels predicted success. The prediction model reached 86.4 percent accuracy in telling outcomes apart. One leukemia case and two serious infections were reported.
Catalog record
| CREATOR | Jingwen Liu, Wen Hu, Shuyan Li, Shurong Hu, Deming Jiang, Yan Chen |
|---|---|
| YEAR | 2026 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 50101 |
| LICENSE | https://creativecommons.org/licenses/by/4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |